Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Assertio Holdings Inc | ASRT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.7851 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.7851 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.7324 - 8.01 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.7851 | USD |
Assertio Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 75.05M | 95.00M | - | 152.07M | -331.94M | -3.49 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Assertio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ASRT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.754 | 0.94 | 0.7324 | 0.8237747 | 1,287,993 | 0.0311 | 4.12% |
| 1 Month | 0.97 | 0.974899 | 0.7324 | 0.8495577 | 798,194 | -0.1849 | -19.06% |
| 3 Months | 0.83 | 1.21 | 0.7324 | 0.9331624 | 973,726 | -0.0449 | -5.41% |
| 6 Months | 2.16 | 2.37 | 0.7324 | 1.10 | 1,248,344 | -1.37 | -63.65% |
| 1 Year | 5.37 | 8.01 | 0.7324 | 3.25 | 1,629,462 | -4.58 | -85.38% |
| 3 Years | 0.56 | 8.01 | 0.419 | 2.98 | 1,433,282 | 0.2251 | 40.20% |
| 5 Years | 4.14 | 8.01 | 0.33 | 1.70 | 2,331,602 | -3.35 | -81.04% |
Assertio Description
| Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |
